Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"We are extremely pleased with the results
great news out
holding years
with 143 down to ......3 no,no,no,no
me too
Iain: Until deals are signed I can’t divulge any information.
[url]www.gomonews.com/...obile-barcode-licensing-competitors-and-lawsuits/
[/url
how much win "socke" better 20+ than 20-
Street: 0,07 today
keep cool
Real-Time Best Bid & Ask
0.02 / 0.0227(1 x 1)Why is size 1?
Save The Date! March 22
Annual Mobile Marketing Day Speaker Laura Marriott
The Annual Mobile Marketing Day 2012
Register early to ensure your seat! Each of these events has sold out and people had to be turned away at the door!
Hear industry experts discuss the state of mobile marketing at this fourth annual event on March 22 in New York, organized by Mobile Marketer in conjunction with the DMA Mobile Marketing Council.
Mobile's maturity over the past year is unprecedented. The opportunities that arose in 2011 and the uptake by marketers in the channel proves that outreach to consumers on the go is the future of marketing. However, brands, ad agencies, retailers, and publishers are still trying to figure out how to integrate mobile into their multichannel mix while dealing with the complexities of the medium, including device and platform fragmentation and lack of advertising standardization.
“Mobile Marketing Day will focus on the state of mobile marketing and how it should fit into the multichannel marketing strategy,” said Giselle Tsirulnik, deputy managing editor of Mobile Marketer and Mobile Commerce Daily.
“Attendees can expect to learn the ins and outs of the most popular mobile sub-channels such as advertising, media, messaging, QR codes, app and Web site development, and location-based marketing,” she said. “Those in attendance will learn how to incorporate various mobile strategies into the 360-degree marketing plan.”
Limited to only 100 executives, the daylong conference is part of a continuing series of educational and informational events run by Mobile Marketer and the DMA Mobile Marketing Council. The event is being held in midtown Manhattan, and is walking distance from Grand Central Station and Times Square. Registration is $99 for DMA Council members, $299 for DMA members, and $499 for non-members; the fee includes breakfast, lunch, and cocktails.
LIMITED NUMBER OF SPONSORSHIPS/TABLETOPS AVAILABLE — RESERVE NOW. Contact Lisa Merizio Smith [lmerizio@the-dma.org]
Agenda
3:00 p.m. – 3:45 p.m.
Debate: Which Channel Will Be the Breakout Star in 2012?
With so many channels to choose from — SMS, mobile ads, mobile search, messaging, mobile Web, mobile apps, QR codes and mobile video — it is hard to foretell which will bring the best ROI. Consumers now expect from mobile phones experiences realized on Web-enabled computers and stores — plus more. Panelists in this session will conduct a lively discussion regarding:
The various mobile channels and how they work for branding and customer acquisition
Which channel will be the breakout star in 2012 and why?
How new forms of mobile marketing and what the future holds
What progress is being made in mobile measurement within the various subchannels of mobile
Best practice tips for 2012 and beyond
Speakers: Laura Marriott, acting-CEO, NeoMedia Technologies
Eric Harber, Chief Operating Officer, Hipcricket
Gary Schwartz, Vice President, Millennial Media
Lisa Abramson, Director of Marketing, Rhythm NewMedia
Alistar Goodman, CEO, Placecas
Moderator: Giselle Tsirulnik, Deputy Managing Editor, Mobile Marketer and Mobile Commerce Daily
Real-Time Best Bid & Ask
0.0136 / 0.0155(1 x 1)Why is size 1
today 0,02 possible ????
nice to read you quipu
..http://www.therepublic.com/view/story/...6a4/CO--Colorado-Goldfields/
Colorado Goldfields submits application in bid to reactivate mill near Silverton
Colorado Goldfields stellt Antrag im Angebot zu Mühle in der Nähe von Silverton reaktivieren
DENVER — Colorado Goldfields Inc. says it's getting closer to reactivating the Pride of the West mill near Silverton in southwest Colorado.
Chief Financial Officer Stephen Guyer said Tuesday the company is "literally knocking on the door of operations."
The company says the Colorado Division of Reclamation, Mining and Safety has received its application for a permit amendment so it can place the mill into active production status. It says the division is scheduled to make a decision on it May 1.
Chief Financial Officer Stephen Guyer said Tuesday the company is "literally knocking on the door of operations."
The company bought the mill in San Juan County in 2007 from Tusco Inc. Colorado Goldfields is trying to reactivate the mill to produce primarily gold, silver, copper, lead and zinc
wait 8 days
Grant 5U19AI073975-02 from National Institute Of Allergy And Infectious Diseases IRG: ZAI1
Abstract: HIV reverse transcriptase (RT) has been an attractive target for HIV drug development, with 11 of the 20 approved drugs targeting RT DMA polymerase activity. However, HIV drug resistance is an increasingly serious clinical problem. New therapeutics are needed, especially those against unaddressed HIV targets, such as HIV RT-associated RNase H (RNH). RNH is underexplored for antiviral therapeutic discovery and development, and very few RNH inhibitors (RNHI) have been identified. This research program, HIV RNase H Natural Product Inhibitors, builds on a novel technology for plant cell culture as a source of novel antiviral agents. We have already identified several natural product RNHI with submicromolar antiviral activity. The proposed studies comprise three projects designed to develop and optimize these and other compounds to be identified from screening an existing 160,000 product library. The iterative research and development program combines the efforts of several investigators from academia and industry with considerable experience in HIV drug discovery and development. Project 1, Isolation and Optimization (Baroudy, Project Leader, Millenia Hope Inc) will isolate and purify natural products from plant cell cultures and carry out semisynthetic optimizations based on SAR developed in the other projects. Project 2, Biochemistry and Virology (Parniak, Program Director, University of Pittsburgh) will characterize the compounds for biological activity to generate data for use in SAR development, conduct detailed mechanism of action analysis, and screen the product library for new RNHI chemotypes. Project 3, Structural and Computational Biology (Arnold, Project Leader, CABM/Rutgers) will determine structures of RT complexed with RNHI for use along with data from Project 2 to develop an SAR to predict modifications to improve potency. Such modifications will be made in Project 1, then characterized in Projects 2 & 3. This iterative process will continue until 2-3 lead candidates and 4-6 backups with low nM potency have been selected to enter extensive preclinical assessment. The research program will have significant impact on public health by developing new anti-HIV therapeutics for use in the treatment of patients infected with HIV strains resistant to the current clinically used drugs
Keywords: biological product
Project start date: 2007-03-05
Project end date: 2012-02-29
5U19AI073975-02 (2008): $896645
zu:
http://www.newswire.ca/en/story/63717/millenia-hope-inc-rece…
"Millenia Hope Inc receives a grant from the National Institutes of Health (USA) to develop new HIV therapeutics in consortium with the University of Pittsburgh and Rutgers University
WILMINGTON, DE, and MONTREAL, April 19 /CNW Telbec/ - Millenia Hope Inc.,
(MLHP.PK - Frankfurt: MLF.F) in consortium with the University of Pittsburgh
and Rutgers University has been selected by the National Institutes of Health
(USA) to receive more than $4.6 M over the next five years for a project "HIV
RNase H natural product inhibitors" to develop novel HIV therapeutics directed
at the under-explored HIV target ribonuclease H (RNase H). This research
program is driven by Phytomics, a unique technology of Millenia Hope Inc., for
the production and isolation of plant cell culture-derived natural products to
inhibit HIV RNase H, a viral target that is essential for HIV-1 replication
but for which there are no drugs in current clinical development.
The NIH award will support the efforts of an outstanding group of
internationally-recognized investigators from three institutions. Dr. Michael
A. Parniak, Professor of Molecular Genetics & Biochemistry at the University
of Pittsburgh and Principal Investigator of this multi-team research effort,
has nearly 20 years experience in HIV research and is regarded as a thought
leader in the discovery of drugs targeting HIV RNase H. Dr. Parniak notes
"This project has an excellent probability of discovering new HIV
therapeutics. The research team we have assembled is world-class, and Millenia
Hope's Phytomics technology provides not only a unique but a readily renewable
resource for the discovery and production of novel HIV drugs."
Dr. Bahige M. Baroudy, President and CSO, Millenia Hope Inc., has
extensive experience in development of new HIV therapeutics and was among the
first to validate HIV entry as a therapeutic target. Structural biologist
Dr. Eddy Arnold at Rutgers is one of the most highly cited HIV research
scientists. Dr. Ronald Levy at Rutgers has developed unique computational
methods to assist in design of new drug entities. The ultimate goal of the
group is to develop a new class of HIV therapeutics that will be effective
against the increasingly prevalent viral strains that are resistant to current
drug therapies.
Dr. Baroudy noted, "Millenia Hope is honored that NIH recognizes our
Phytomics technology as a source for novel HIV therapeutics. The NIH support
and the willingness of world-class scientists; Drs. Parniak, Arnold and Levy
to collaborate with us in the development of new drugs for the treatment of
HIV infection is an excellent validation of of our Phytomics technology and
our R&D programs." Dr. Baroudy also stated "Millenia Hope's accomplishments
are a tribute to the sound scientific infrastructure in the Province of
Quebec, Canada. We are also indebted to our shareholders who supported us over
the years, especially in acquiring the patent in 2006 that describes the
compounds that inhibit HIV RNase H. This collaborative research project with
Drs. Parniak, Arnold and Levy will realize our objective of developing a new
therapy for HIV." vom April 19, 2007 8:38 AM
# 3 on breakout Board
nothing as usual
i think there comes nothing, i wait two years
for a livesign
#13 breakout board
Breakout-Board #15
best regards, from cologne germany
Nov
18
Wallstreetdiscussions’ Penny Pick of the Day NEOM Categories:
Penny Pick of the DayPrint this page
Email This Post
by Roy Jimenez
November 18, 2011
.
NeoMedia Technologies, Inc.
NeoMedia Technologies, Inc. (NeoMedia) utilizes the mobile phone by leveraging barcodes (printed symbols) as a mechanism to link brands, advertisers, carriers, retailers and consumers using the mobile Internet. With the barcode ecosystem technology, NeoMedia transforms mobile phones with cameras into barcode scanners, which provide instant access to mobile Web content whenever a barcode is scanned. NeoMedia provides the infrastructure to facilitate mobile barcode scanning and its associated commerce globally. The mobile barcode ecosystem software reads and transmits data from one-dimensional (1D) and two-dimensional (2D) barcodes to its intended destination. The code management and clearinghouse platforms create, connect, record, and transmit the transactions embedded in the barcodes. In order to provide mobile marketing solutions, NeoMedia also offers barcode scanning hardware that reads barcodes displayed on mobile phone screens.(Source:Reuters)
NEOM has recently gaped down and should eventually revisit the spot it gaped down off of. We will be exiting once it reaches there.
up today
whats going today, new begin for arise ??
i dont, but they must cover soon
strong buy @ barchart
insert-text-here
@nitra, I'm waiting for exactly this time to a comeback, since then I've kept all my shares .... now it is time to reach the old heights again
tick tack, tick tack
ok thanks
@raider....
and when comes news from millenia ??
only a life-sign...
i invest lot of money, before 3 years
Happy Birthday
looks here http://www.wallstreet-online.de/diskussion/1168864-21-30/millenia-hope-inc-neue-strategie#neuster_beitrag" rel="nofollow" target="_blank" >http://www.wallstreet-online.de/diskussion/1168864-21-30/millenia-hope-inc-neue-strategie#neuster_beitrag
the user quipu makes a wonderfull job
the webside of millenia is under construction...
why...comes news in a few time ???
is anyone here ??????